Bahl & Gaynor Inc. Acquires 859,677 Shares of Johnson & Johnson $JNJ

Key Points

• Bahl & Gaynor Inc. increased its stake in Johnson & Johnson by 64.7% in Q1, owning approximately 2.19 million shares worth $362.87 million.
• Johnson & Johnson announced a quarterly dividend of $1.30 per share, to be paid on September 9th, representing a 2.9% yield.
• Research analysts generally have a Moderate Buy consensus rating on Johnson & Johnson, with a price target averaging $176.29.

Bahl & Gaynor Inc. grew its position in shares of Johnson & Johnson (NYSE:JNJ - Free Report) by 64.7% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 2,188,091 shares of the company's stock after purchasing an additional 859,677 shares during the period. Johnson & Johnson comprises about 1.8% of Bahl & Gaynor Inc.'s holdings, making the stock its 15th largest holding. Bahl & Gaynor Inc. owned approximately 0.09% of Johnson & Johnson worth $362,873,000 at the end of the most recent reporting period.

A number of other large investors also recently modified their holdings of JNJ. Highline Wealth Partners LLC lifted its holdings in shares of Johnson & Johnson by 51.8% in the 1st quarter. Highline Wealth Partners LLC now owns 252 shares of the company's stock worth $42,000 after acquiring an additional 86 shares during the last quarter. Stone House Investment Management LLC bought a new stake in Johnson & Johnson in the first quarter worth $47,000. von Borstel & Associates Inc. purchased a new stake in Johnson & Johnson during the first quarter valued at about $49,000. Capital A Wealth Management LLC bought a new position in shares of Johnson & Johnson during the fourth quarter valued at about $50,000. Finally, Harvest Fund Management Co. Ltd purchased a new position in shares of Johnson & Johnson in the first quarter worth about $52,000. 69.55% of the stock is owned by hedge funds and other institutional investors.

Johnson & Johnson Trading Up 0.1%

Shares of NYSE:JNJ traded up $0.1680 on Friday, hitting $179.0980. The company had a trading volume of 9,523,149 shares, compared to its average volume of 8,657,504. The firm's 50-day simple moving average is $163.48 and its two-hundred day simple moving average is $159.30. The firm has a market capitalization of $431.33 billion, a price-to-earnings ratio of 19.15, a P/E/G ratio of 2.28 and a beta of 0.41. The company has a quick ratio of 0.76, a current ratio of 1.01 and a debt-to-equity ratio of 0.50. Johnson & Johnson has a 1 year low of $140.68 and a 1 year high of $181.16.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last announced its quarterly earnings results on Wednesday, July 16th. The company reported $2.77 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.68 by $0.09. Johnson & Johnson had a net margin of 25.00% and a return on equity of 32.49%. The company had revenue of $23.74 billion for the quarter, compared to analysts' expectations of $22.85 billion. During the same quarter in the previous year, the company earned $2.82 earnings per share. Johnson & Johnson's quarterly revenue was up 5.8% on a year-over-year basis. Johnson & Johnson has set its FY 2025 guidance at 10.800-10.900 EPS. Equities analysts anticipate that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Tuesday, September 9th. Stockholders of record on Tuesday, August 26th will be paid a $1.30 dividend. This represents a $5.20 dividend on an annualized basis and a dividend yield of 2.9%. The ex-dividend date is Tuesday, August 26th. Johnson & Johnson's dividend payout ratio (DPR) is presently 55.61%.

Wall Street Analyst Weigh In

JNJ has been the topic of a number of analyst reports. Morgan Stanley lifted their price target on Johnson & Johnson from $171.00 to $176.00 and gave the stock an "equal weight" rating in a research note on Thursday, July 17th. Leerink Partners lowered shares of Johnson & Johnson from an "outperform" rating to a "market perform" rating and lowered their price target for the company from $169.00 to $153.00 in a report on Tuesday, May 13th. UBS Group raised their price target on shares of Johnson & Johnson from $180.00 to $190.00 and gave the stock a "buy" rating in a report on Thursday, July 17th. Citigroup upped their price objective on shares of Johnson & Johnson from $185.00 to $200.00 and gave the company a "buy" rating in a research note on Thursday. Finally, Royal Bank Of Canada raised their target price on Johnson & Johnson from $181.00 to $185.00 and gave the stock an "outperform" rating in a research note on Thursday, July 17th. Two equities research analysts have rated the stock with a Strong Buy rating, nine have issued a Buy rating and nine have given a Hold rating to the company's stock. According to MarketBeat, Johnson & Johnson has an average rating of "Moderate Buy" and an average target price of $176.29.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.